This was an excellent report on two recent randomized trials which found that a new osteoporosis drug, denosumab, reduced the rate of fractures and increased bone density in at-risk men and women. While the results appear promising, the story tempered excitement by providing potential annual cost estimates of the drug at $10,000 and pointing out that Amgen, the manufacturer of denosumab, funded both of the studies, handled data collection and analysis and took part in writing the journal articles. Additionally, many of the researchers involved were in receiving fees from Amgen. The story also discusses the drug’s potential harms and compares it to existing osteoporosis treatments. Providing outcome data in terms of absolute risk in addition to relative risk would have further strengthened this story.
Pricing for this drug is not yet available; however, the story suggests that it could be expensive, with similarly engineered drugs costing more than $10,000 a year. In addition, the costs of currently prescribed osteoporosis medications are provided.
The relative risk reduction for each of the trials is provided, but the story fails to provide the absolute risk reduction (62% of what?). The writer also mentions that spine bone density loss in the men receiving denosumab was “far smaller” compared to the placebo group; however, the reader is not given any quantitative data to determine the clinical significance of this.
In addition to comparing the absolute risk reduction observed in the denosumab group to the placebo group, it would have been helpful to the reader to know what the risk reduction was for approved and potentially more affordable medications.
Citing the FDA’s review of denosumab, as well as the adverse risks reported in the trials, the story mentions that this drug is associated with an increased risk of skin infections and some tumors. The story also points out that its long-term effects on cancer risk and the immune system are unknown.
This story adequately describes the methodology of each trial, as well as the patient population. The story also does a service by alerting the reader that the drug manufacturer, Amgen, funded both of the studies and nearly all of the researchers were receiving fees from said manufacturer. Additionally, it was pointed out that Amgen designed the trials, handled data collection and analysis, and assisted in writing the journal articles.
This story did not exaggerate the prevalence or seriousness of osteoporosis.
Several independent sources were interviewed for this story. The writer also points out that both trials were paid for by Amgen, the manufacturer of denosumab, and nearly all the researchers were employed by the company or received consulting or advisory fees from them.
This story discusses several alternative drug options for treating osteoporosis, including vitamins, pills, patches, nasal sprays, and intravenously and subcutaneously injected drugs. Comparisons in efficacy between denosumab and some of these alternatives are provided. More information comparing the absolute risk reduction for spine fractures would have been a nice addition, as well.
The story makes it clear that the study drug, denosumab, is not yet approved by the FDA, but indicates that it could be available this fall.
Up front the story states that this is a “first-of-its-kind” drug treatment for osteoporosis.
This piece included several independent sources and therefore, does not rely on the news release.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like